» Articles » PMID: 29407687

Cognitive Deficits in Individuals with Methamphetamine Use Disorder: A Meta-analysis

Overview
Journal Addict Behav
Date 2018 Feb 7
PMID 29407687
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Methamphetamine has long been considered as a neurotoxic substance causing cognitive deficits. Recently, however, the magnitude and the clinical significance of the cognitive effects associated with methamphetamine use disorder (MUD) have been debated. To help clarify this controversy, we performed a meta-analysis of the cognitive deficits associated with MUD.

Methods: A literature search yielded 44 studies that assessed cognitive dysfunction in 1592 subjects with MUD and 1820 healthy controls. Effect size estimates were calculated using the Comprehensive Meta-Analysis, for the following 12 cognitive domains: attention, executive functions, impulsivity/reward processing, social cognition, speed of processing, verbal fluency/language, verbal learning and memory, visual learning and memory, visuo-spatial abilities and working memory.

Results: Findings revealed moderate impairment across most cognitive domains, including attention, executive functions, language/verbal fluency, verbal learning and memory, visual memory and working memory. Deficits in impulsivity/reward processing and social cognition were more prominent, whereas visual learning and visuo-spatial abilities were relatively spared cognitive domains. A publication bias was observed.

Discussion: These results show that MUD is associated with broad cognitive deficits that are in the same range as those associated with alcohol and cocaine use disorder, as recently shown by way of meta-analysis. The prominent effects of MUD on social cognition and impulsivity/reward processing are based on a small number of studies, and as such, these results will need to be replicated. The functional consequences (social and occupational) of the cognitive deficits of methamphetamine will also need to be determined.

Citing Articles

Decreasing β-Catenin Leads to Altered Endothelial Morphology, Increased Barrier Permeability and Cognitive Impairment During Chronic Methamphetamine Exposure.

Qiu H, Zhang M, Chen C, Wang H, Yue X Int J Mol Sci. 2025; 26(4).

PMID: 40003980 PMC: 11854931. DOI: 10.3390/ijms26041514.


Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder.

Khan R, Turner A, Berk M, Walder K, Rossell S, Guerin A Biomolecules. 2025; 15(2).

PMID: 40001609 PMC: 11852989. DOI: 10.3390/biom15020306.


Recent advances in nanotherapeutics for HIV-associated neurocognitive disorders and substance use disorders.

Lomas C, Dubey R, Perez-Alvarez G, Lopez Hernandez Y, Atmar A, Arias A Nanomedicine (Lond). 2025; 20(6):603-619.

PMID: 39963928 PMC: 11902879. DOI: 10.1080/17435889.2025.2461984.


Trial protocol of an open-label pilot study of oral ltrexone-propion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial).

Siefried K, Acheson L, Clifford B, Moller C, Brett J, Christmass M BMJ Open. 2025; 15(2):e092032.

PMID: 39920060 PMC: 11808914. DOI: 10.1136/bmjopen-2024-092032.


Fusion Model Using Resting Neurophysiological Data to Help Mass Screening of Methamphetamine Use Disorder.

Chen C, Tsai M, Wu E, Sheng S, Lee J, Lu Y IEEE J Transl Eng Health Med. 2025; 13:1-8.

PMID: 39911774 PMC: 11793485. DOI: 10.1109/JTEHM.2024.3522356.